Aim: To evaluate the activity, safety and long-term survival of patients after preoperative oxaliplatin and 5-fluorouracil chemoradiation therapy in locally advanced rectal cancer (LARC).Patients with resectable, T3-4 and/or nodal involvement rectal adenocarcinoma were treated with oxaliplatin 60 mg/m(2) weekly and 5-fluorouracil 200 mg/m(2)/d infused continuously for five days, over a period of five weeks, and radiotherapy (45 Gy/25 fractions). The primary end-point was pathological complete response (ypCR). Safety, overall survival (OS) and relapse-free survival (RFS) were secondary end-points.Sixty-six patients were treated. Grade 1-2 diarrhea was the most common adverse event. The ypCR rate was 16.7\% (95\% confidence interval=7.7-25.7\%). After a median follow-up of 73.5 months, 23 patients (34.8\%) had experienced relapse. Five-year actuarial RFS and OS rates were 64\% and 73\%, respectively. Five-year actuarial RFS was 91.7\% in the ypCR group versus 57.8\% in non-ypCR cases.Long-term local control and survival after this very well-tolerated regimen appear encouraging.
Long-term results of preoperative 5-fluorouracil-oxaliplatin chemoradiation therapy in locally advanced rectal cancer / E., F., F., P., R., C., S., B., S., G., F., L., F. V., N., E., A., P. L., L., L., R., P., D., P., C., Cascinu, S., A., A.. - In: ANTICANCER RESEARCH. - ISSN 0250-7005. - 33:2(2013), pp. 725-730.
Long-term results of preoperative 5-fluorouracil-oxaliplatin chemoradiation therapy in locally advanced rectal cancer.
CASCINU, Stefano;
2013
Abstract
Aim: To evaluate the activity, safety and long-term survival of patients after preoperative oxaliplatin and 5-fluorouracil chemoradiation therapy in locally advanced rectal cancer (LARC).Patients with resectable, T3-4 and/or nodal involvement rectal adenocarcinoma were treated with oxaliplatin 60 mg/m(2) weekly and 5-fluorouracil 200 mg/m(2)/d infused continuously for five days, over a period of five weeks, and radiotherapy (45 Gy/25 fractions). The primary end-point was pathological complete response (ypCR). Safety, overall survival (OS) and relapse-free survival (RFS) were secondary end-points.Sixty-six patients were treated. Grade 1-2 diarrhea was the most common adverse event. The ypCR rate was 16.7\% (95\% confidence interval=7.7-25.7\%). After a median follow-up of 73.5 months, 23 patients (34.8\%) had experienced relapse. Five-year actuarial RFS and OS rates were 64\% and 73\%, respectively. Five-year actuarial RFS was 91.7\% in the ypCR group versus 57.8\% in non-ypCR cases.Long-term local control and survival after this very well-tolerated regimen appear encouraging.
Pubblicazioni consigliate
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris
